| 摘要: |
| 目的：探讨维生素A（VitA）在儿童支气管哮喘治疗中的临床应用价值。方法：将我院2016年8月至2017年12月收治的年龄4~14岁支气管哮喘患儿120例随机分为观察组和对照组各60例，对照组患儿采用全球哮喘防治创议（GINA）推荐方案治疗，其中糖皮质激素选用沙美特罗替卡松粉吸入剂（舒利迭），观察组患儿在对照组基础上加用适量维生素A（VitA）口服辅助治疗，另选同期健康体检儿童60例作为正常组，检测三组儿童的血清Vit A水平、第1秒钟用力呼气容积（FEV1）、用力肺活量（FVC）、FEV1占预计值的百分比（FEV1%），评价临床疗效，并进行比较分析。结果：观察组、对照组、正常组儿童入院时（治疗前）的血清VitA水平分别为（0.79±0.08）μmol/L、（0.76±0.12）μmol/L、（1.30±0.14）μmol/L，观察组与对照组比较差异无统计学意义（P>0.05），但均低于正常组（P均<0.05）。观察组患儿治疗1个月、治疗2个月的血清VitA水平分别为（1.31±0.14）μmol/L、（1.34±0.16）μmol/L均高于治疗前（P均<0.05）。治疗1个月，两组患儿的FEV1、FVC、FEV1/FVC、FEV1%均大于治疗前（P均<0.05），但两组间比较差异无统计学意义（P均>0.05）；治疗2个月，观察组患儿的FEV1、FVC、FEV1/FVC、FEV1%均大于对照组（P均<0.05）。治疗2个月后，观察组的总有效率为90.00%，高于对照组的76.67%（χ2=15.56，P<0.05）。结论：适量VitA口服辅助GINA方案治疗儿童支气管哮喘疗效确切，因为VitA具有抗氧化功能，可以增强机体免疫力，起到抗炎、协调免疫因子、改善呼吸功能的作用，从而提高治疗效果。 |
| 关键词: 维生素A 儿童 支气管哮喘 肺功能 |
| DOI：doi:10.13407/ j.cnki.jpp.1672-108X.2019.05.006 |
|
| 基金项目: |
|
| Vitamin A Combined with Salmeterol Xinafoate and Fluticasone Propionate Powder for Inhalation in the Adjuvant Treatment of Children with Asthma |
| Yu Chunmei, Chen Cong, Wang Bin, Wang Zhihui, Chen Jing, Wang Chengxiu |
| (The Fifth People’s Hospital of Chongqing, Chongqing 400062, China) |
| Abstract: |
| Objective: To investigate the clinical application value of Vitamin A (VitA) in the treatment of bronchial asthma in children. Methods: Totally 120 children aged from 4 to 14 years old with bronchial asthma admitted into our hospital from Aug. 2016 to Dec. 2017 were randomly divided into the observation group and the control group, with 60 cases in each group. The control group was given the treatment recommended by the Global INitiative for Asthma (GINA), salmeterol xinafoate and fluticasone propionate powder for inhalation (shulidipine) was selected as the glucocorticoid, and the observation group received an appropriate amount of VitA on the basis of the control group. Another 60 healthy children in the same period were selected as the normal group. The serum Vit A levels, forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), and percentage of FEV1 (FEV1%) of three groups were determined to evaluate, analyze and compare the clinical efficacy. Results: The serum VitA levels of the observation group, the control group and the normal group were respectively (0.79±0.08) mol/L, (0.76±0.12) mol/L and (1.30±0.14) mol/L, the difference between the observation group and the control group was not statistically significant (P>0.05), but the serum VitA levels of observation group and the control group were lower than those of the normal group (P<0.05). After treatment of 1 month and 2 months, the serum VitA levels in the observation group were respectively (1.31±0.14) μmol/L and (1.34±0.16) μmol/L, higher than those before treatment (P<0.05). After treatment of 1 month, FEV1, FVC, FEV1/FVC, and FEV1% in two groups were greater than before treatment (P<0.05), but the difference was not statistically significant (P>0.05). After treatment of 2 months, FEV1, FVC, FEV1/FVC, and FEV1% of the observation group were higher than those of the control group (P<0.05). After treatment of 2 months, the total effective rate of the observation group was 90.00%, higher than that of the control group 76.67% (χ2=15.56, P<0.05). Conclusion: Appropriate amount of VitA orally combined with adjuvant treatment of children with bronchial asthma is significant, VitA has an antioxidant function, which can enhance the body’s immunity, play an anti-inflammatory role in coordinating immune factors and improving respiratory function, thus improving the therapeutic effects. |
| Key words: vitamin A children bronchial asthma pulmonary function |
